checkAd

     159  0 Kommentare Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020 - Seite 4

    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen
    Seite 4 von 4

    Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020 - Seite 4 Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a …